Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCG 101

Next Previous
Drug Profile

SCG 101

Alternative Names: Hepatitis B virus TCR T-cell therapy - SCG Cell Therapy; SCG-101

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SCG Cell Therapy
  • Developer Peking Union Medical College Hospital; SCG Cell Therapy
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Liver cancer

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Monotherapy, Second-line therapy or greater) in China (IV, Infusion)
  • 07 May 2025 Efficacy and adverse events data from phase I clinical trials in Liver cancer presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)
  • 07 May 2025 SCG Cell Therapy completes enrolment in its phase I trial for Liver cancer in China (NCT06617000)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top